These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11756178)

  • 1. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
    Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
    Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
    Shman TV; Belevtsev MV; Buglova SE
    Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.
    Hefti E; Blanco JG
    J Pediatr Hematol Oncol; 2016 May; 38(4):283-7. PubMed ID: 26907658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ
    Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
    Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
    Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
    Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
    Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
    Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
    Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
    Rao A; Hills RK; Stiller C; Gibson BE; de Graaf SS; Hann IM; O'Marcaigh A; Wheatley K; Webb DK
    Br J Haematol; 2006 Mar; 132(5):576-83. PubMed ID: 16445830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
    Frost BM; Gustafsson G; Larsson R; Nygren P; Lönnerholm G
    Leukemia; 2000 May; 14(5):943-4. PubMed ID: 10803530
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
    Styczynski J; Wysocki M; Dluzniewska A; Juraszewska E; Balwierz W; Czyzewski K; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Stanczak E; Malinowska I; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Kapuscinska L; Szczepanek J; Kolodziej B; Rafinska B; Kubicka M
    Anticancer Res; 2008; 28(3B):1927-31. PubMed ID: 18630483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
    Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
    Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological late effects of treatment for acute leukemia in children with Down syndrome.
    Roncadin C; Hitzler J; Downie A; Montour-Proulx I; Alyman C; Cairney E; Spiegler BJ
    Pediatr Blood Cancer; 2015 May; 62(5):854-8. PubMed ID: 25545182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
    Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
    Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
    Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
    Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.
    Pieters R; Huismans DR; Loonen AH; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
    Lancet; 1991 Aug; 338(8764):399-403. PubMed ID: 1678081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
    Goemans BF; Zwaan CM; Harlow A; Loonen AH; Gibson BE; Hählen K; Reinhardt D; Creutzig U; Heinrich MC; Kaspers GJ
    Blood; 2005 Nov; 106(10):3532-7. PubMed ID: 16051737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.